# Fulcrum Therapeutics (FULC) — Earnings

FULC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/fulc/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q1 2026 |
| Period end | Mar 31, 2026 |
| EPS actual | −$0.25 |
| EPS estimate | −$0.29 |
| EPS surprise | +15.05% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Apr 27, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1680581/000119312526178814/fulc-20260331.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/aa6f3690-4147-8a0d-63cf-3aa9d6d07164.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q1 2026 | Apr 27, 2026 | −$0.29 | −$0.25 | 15.05% | — | — |
| Q4 2025 | Feb 24, 2026 | −$0.30 | −$0.31 | -3.64% | — | — |
| Q3 2025 | Oct 29, 2025 | −$0.29 | −$0.31 | -5.51% | — | — |
| Q2 2025 | Jul 29, 2025 | −$0.29 | −$0.28 | 3.45% | — | — |
| Q1 2025 | May 1, 2025 | −$0.29 | −$0.28 | 4.76% | — | — |
| Q4 2024 | Feb 25, 2025 | −$0.28 | −$0.31 | -10.05% | — | — |
| Q3 2024 | Nov 13, 2024 | −$0.40 | −$0.35 | 11.68% | — | — |
| Q2 2024 | Jul 31, 2024 | −$0.41 | $0.87 | 311.17% | $14.8M | $80.0M |
| Q1 2024 | May 13, 2024 | −$0.44 | −$0.43 | 1.71% | $416,667.00 | — |
| Q4 2023 | Feb 27, 2024 | −$0.43 | −$0.40 | 6.04% | $552,718.00 | $871,000.00 |
| Q3 2023 | Nov 7, 2023 | −$0.44 | −$0.39 | 11.50% | $1.1M | $759,000.00 |
| Q2 2023 | Aug 3, 2023 | −$0.45 | −$0.38 | 16.26% | $1.1M | $880,000.00 |
| Q1 2023 | May 15, 2023 | −$0.46 | −$0.41 | 11.47% | $1.1M | $295,000.00 |
| Q4 2022 | Mar 9, 2023 | −$0.49 | −$0.50 | -2.06% | $1.9M | $685,000.00 |
| Q3 2022 | Nov 8, 2022 | −$0.61 | −$0.51 | 16.69% | $2.5M | $1.2M |
| Q2 2022 | Aug 11, 2022 | −$0.66 | −$0.83 | -25.62% | $3.0M | $1.9M |
| Q1 2022 | May 9, 2022 | −$0.63 | −$0.64 | -2.09% | $3.9M | $2.6M |
| Q4 2021 | Mar 3, 2022 | −$0.73 | −$0.58 | 20.27% | $2.7M | $5.1M |
| Q3 2021 | Nov 4, 2021 | −$0.65 | −$0.57 | 11.91% | $2.3M | $4.9M |
| Q2 2021 | Aug 10, 2021 | −$0.65 | −$0.60 | 8.05% | $2.4M | $4.4M |

## Frequently Asked Questions

### When did Fulcrum Therapeutics (FULC) last report earnings?

Fulcrum Therapeutics last reported on Apr 27, 2026, covering fiscal Q1 2026.

### Did FULC beat earnings estimates?

Yes. Fulcrum Therapeutics reported EPS of −$0.25 for Q1 2026 against a −$0.29 estimate — a 15.05% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).